Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America

Table 4 Univariate analysis assessing the relative risk (95%CI) of inflammatory bowel disease patients under treatment who developed active tuberculosis from a referral center

Variable	Total, n (%)	Active tuberculosis, n (%)	RR (95%CI)	P value
Sex				0.027
Female	188 (62.5)	2 (1,1)	1.0
Male	113 (37.5)	6 (5.3)	4.99 (1.02-24.3)
Age (yr)				0.158
18-40	185 (61.5)	3 (1.6)	1.0
41-91	116 (38.5)	5 (4.3)	2.66 (0.65-10.91)
IBD type				0.487
RCU	186 (61.8)	4 (2.2)	1.0
CD	115 (38.2)	4 (3.5)	1.61 (0.41-6.34)
Latent TB				< 0.001
No	276 (93.2)	5 (1.8)	1.0
Yes	20 (6.8)	3 (15.0)	8.28 (2.13-32.18)
Azathioprine				0.013
No	199 (66.1)	2 (1.0)	1.0
Yes	102 (33.0)	6 (5.9)	5.85 (1.20-28.48)
Anti-TNFα				0.034
No	240 (79.7)	4 (1.7)	1.0
Yes	61 (20.3)	4 (6.5)	3.93 (1.01-15.29)
Aza + Anti-TNFα				< 0.001
No	271 (90.0)	4 (1.5)	1.0
Yes	30 (10.0)	4 (13.3)	9.03 (2.38-34.28)

RR: Relative risk; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn's disease; TB: Tuberculosis; Anti-TNFα: Anti-tumor necrosis factor alpha; Aza: Azathioprine.